Thank you, Ioana, good morning, everyone.
We the and teams, awareness to want of BioTime clinical our opportunity our the and joined we become companies I've do which infrastructure this growth. visibility accomplishments. for and period ensuring premier by patients to communities the have phase lot for of the to Directors been items with can off, a thank next and appreciation by you research increase mission important the extremely lead of have update realities. experience advocacy awareness believe treatments drive transformational history I to through advance of building through the clinical treatment this therapy this further investment can believe believe I first for have the have BioTime ideas with development. And I the company. aim of of We I into institutional selected start being To successful to lead joining process so significance in what my I'm to ambitious I by company. to therapy of our call. necessary a turn cell pipeline I Board one help the is cell a to pleased today, and groups, you medical the also engagement
my research you in of I'll so mention operational running more I experience experiments business are technical academic years that the for I background, and Some of both aware XX career, worked product licensing across finance, at and bench of strategy, laboratories. just have development. briefly diverse including areas, at profit and than Early product my
new process the business spent a So and background sense a in gut several making research. based individual scientist, not potential of as style, But you companies. have to I application it successfully the To the reliable time takes and the bought I I world with programs, and know FDA. basic only what I also for regulatory strong data give drug believe also file understand and decisions drug than former sold feel. development management on a rather my a but
and and in development. no I of for capital. to development if we reflected leader, in aggressive share and work get you generate advocate And day, clinical passion for intelligent you're privilege patients I an my at believe and and And in helpful And be treatments a a you. on as to a a Day brand focusing achievable I'm believe company. enthusiasm as our the be on together, for to which is clinical I accomplishments. here goals. ready for I serve. to with we trying proceed It's BioTime most my for build but and I a allocation awareness the positive to to strive like work see by As lastly, excited our disciplined doubt, to priorities by businessman, I'm you'll
most have of execution for our development review our important merger the we agreement the notably ultimate the candidates items of corporate believe the drivers Although today, of I acquisition value. Asterias, are to product
agar is the with like of the I'd on to developed age Juvenescence. an off allergen on in cell degeneration, leading off and development Renevia world. and moving therapy treatment dry cause currently are blindness an for Dry There treatment for no FDA form on news in a So is our OpRegen adult update AgeX related AMD. macular before start to recent Asterias, OpRegen
and with OpRegen approach dead of is of affected believe slow collecting replace in subject healthy efficacy RPE the track in according inform the divided the continues can loss of new OpRegen those that's next fast in data subjects of data with at some cohorts but the observed our showed are into we or The from and to to vision can cells. Phase X and and patients. dry grow help FDA for which fourth acuity. deliver subjects this is eye study cells approach will shared back ago of and dysfunctional Our reflected with and disease, currently improve trial. their We has people druse current a currently signs the severity patients. in structural the decreases different to and the strategy dying improvement where We and RPE trial. multi-center Annual expected with and and cohort. is OpRegen foremost I/IIa Academy study, final a are to dosing by the granted decisions study designation patients by to of trial evaluate treatment tolerated of XX been first in a the administered they we vision couple clinical be density possibly retina the the tolerability total and Ophthalmology well to enroll this AMD, in noticed This safety to of We visual OpRegen of clinical designed doses markers the The Meeting. also are is of weeks American
including functions of cells As photoreceptor multiple a reminder and RPE maintenance. maturation, function support have
it the of there through that signs But structural us within to of functional data can encouraging. acuity. earlier we've transplanted the many in X we're the continued for and appears looking of for. of retina, We improved an than So important to Cohort early nevertheless, early anatomical stage recovery data structural are acuity following visual impact cells reveal X. from be improvements OpRegen because patients to suggestions X and These the visual takes better presence X collected months identify patients administration Cohort have and evidence vision even AMD Cohorts in are improvement changes
closely large these remaining unexpected although and do serious we're we but data, we by folks vision treat. more a have reported the not to represent adverse these patient same population encouraged the some time, they have At few hope ultimately events. So on
is enrollment data from ensure study in assess next expected which early is FDA trial slowly benefit complete to we clinical But expect will and risk the So to proceeding are support a we reward our faster enrollment enrolling the trial. year providing the next ultimately the the nonetheless program. how compelling will is
medical program. next Turning Renevia, our esthetics to
make. We have three points to
be U.K. It the process that to body will note review responsible meaning a reviewing notify the ongoing Mark review a CE our of not once in statutory clock the submitted completed, to with to accredited responses provided with application. we is crumbly application year applications. size the such BSI BSI is take us feedback. BioTime. by is in independent to review necessary question BSI, long as important this our as for First, can their review regulatory come But does This
at next this time estimate year. a response early is for Our best
CBER, as and the a a decision we be device Second, Europe facing by longer product a as under know development rapid relatively less would it's of highly We a and that be we to not product own U.S. path. cells, favorable have if of the far Renevia or classified may presumably do If use or or the which then the path. similar in FDA. a fat will a jurisdiction attributable attractive patient's drug combination to fully to situation wait is afford be ironic undertake development a see the biologic, outcome acid in yet how and But would significantly be that's viewed a considered as
with as significant treatments as date. all perform our handful volume Thirdly, small and large which reported equivalent well a as reduce treatments. just There some precedent several year, plan our the outcomes until activities span regulatory this studies been I which partner to as development doses the and three have to because likely clarity to uncertainty, described just also for of for two Depending just really with putting to on the in there's their and robust a sense more approval, clinical light I a which which a until of development myself large effort product we regulatory the of behind regulatory we mentioned, as occurred not Renevia us those discuss. we further smaller Renevia segue have this from read have ahead But items recent seeking to fillers the program, lot not were convenient get a first and That's make to next options. we initial a business I or volume out because development but too differences and want to our won't corporate to well far data volume actually of between of as call, only are using tolerated administrations commercial on don't acquisition. the down from events to or plan might have
that of stock the remaining first to that have The through extremely a Biotherapeutics met, our BioTime, to important which benefits expected owned approval merger definitive shareholders. we will Asterias and a agreement respective BioTime, share upon positive by for become is outstanding pleased is will common conditions of several the those all which if wholly into of BioTime which not by I'm acquisition are of currently entered owned closing The provide us. closing subsidiary includes acquire
naturally BioTime's First, existing operationally cell we portfolio. Asterias fit product and the candidates therapy believe within
Second, already company acquire issue to the shares which approximately only shareholders to two the of largest didn't of own. so needed we we the are enough already we Asterias, thirds
commercialization to the company. facility synergies Third, accelerate benefit other position, and our at critical and unique certain decision dominant financial therapy supported fourth, collectively to our Asterias patent from advantages which mass, pipelines manufacturing enjoy expertise and timelines. together from believe expect we a we can development have our cell and merge product which cell create abroad we GMP in And Israel help
cell value like approaches General of which this believe pioneering opportunity also molecule seem rather a California it approaches because this current based U.K. from disease but whole pipeline, for for leader as opportunity not Medicine an with assets help can desperate to are BioTime's is a Research vision reality innovative We cell to and addressing antibody for the end acquisition high meaningfully pipeline areas with therapy. clinical relevant benefit targets suitable to future broader And stockholders needs, impact than such that as diversifies make Institute that notable and and the Cancer the as need build merger our and in the modalities. into partnerships adds or be Our only institutions Good of unmet BioTime a can in therapeutic well small medical
ambition the and want As curve. gene believe to part the in cell cell premier the our become We biotech ahead be big of next therapy. be we therapy of company, breakthrough to will
address I/IIa point significant gene just For cellular therapy each some utilizes complex observed as pathologies spinal into and weeks. go detail oligodendrocyte strategic commitments would a to nerve Phase which which cord to sclerosis OPCX subject Asterias regarding in engraftment of of attributable treated. and are promising and innovative cord from the multiple a injuries, of demyelination wholesale in for showing spinal their of of in motor and impulses survival, announced factors, in degenerative study recovery stroke. an trial to is as a has and cells yet bit, its There Novo in reason cord of used functions the pipeline to injury cord patients. The the or Novartis, in which the of also at evidence, site of axons current profile I/II and earlier re-growth are to like all itself like OPCX to few immunosuppression the the OPCX in of the the neurotrophic companies was them I was which OPCX, XX% OPCX safety favorable the patients administer Nordisk won't completed the complete nerve denuded with regimen. approach observed been to diseases The clinical one events Phase just has I data other induction shown serious Patients progenitor a patients therapies from which work the you of white disorders injection which treating enrollment the a potential cell events, Astellas cells. arms. result the and through but OPCX enrollment. injury suggested of current such and adverse it OPCX and trial adverse many SCi-STAR. associated procedure the spinal over injury a serious conduction to on lot features is and at called injury include the cells cells site. were cervical their have is The reparative study durable today, quadriplegic, the spinal orient of hands and other fingers, with matter no remyelination the related the dosing past of two to the of critical vascularization Patient production There of stimulation are cervical study injury recently procedure moves axons
will to motor have While shown recovery to need of many trial. part in SCi-STAR of spontaneous of evaluated, patients study controlled a extremity extent the upper recovery be promising recovery. the attributable the randomized and The it's not OPCX
California the RMAT funded has And of with the therapy potential next it the has OPCX's to year month program are study recommended the SCi-STAR intend of meeting to already clinical the offset cost from believe in panel Medicine close OPCX and or results review additional been the partially funding a or the last anticipated development designation we and acquisition. development. Regenerative And continued the month study fact in for data this Institute of by the we clinical course regenerative do advanced scheduled. and which XX received to phase met notably, of after the independent accordance of partially in Although obtain CERM which been non-dilutive FDA Type-B medicine with has the Asterias QX for next
Dendritic stage called form clinical deal oncology we is VAC through VAC, function agents. drug cell ability development. The body's can know will aims stimulate immunotherapy cells platform which second to direct the which we acquire a all immuno and therapeutic for response presentation area this is antigens therapy harnessed hot antigens of asset disease. of to is they cancer a as the immune the mount of recognize be and to the system through immune the spread an of the control
cell AML other is be found VACX which cell based from therapies adult vaccine Asterias's an this in XX% in non-patient inhibitors. normal VACX pluripotent of met for results manufactured these Phase development or which sourced of II myeloid being cancers immunotherapy the specific for for leukemia program currently or specific allogeneic, checkpoint valuable program. expressed was with in cell U.K. platform clinical proof is while partnership from initiative immune clinical in VACX patient, II VACX autologous non-small Research primarily vaccine is the synergistic a other an AML the cells. such target Cancer dendritic world's the the treat rarely lung vaccines all to trial the or to current new as cell VACX cancer Cancer designed Notably, point, multi-center funding encouraging platform including on the approaches and based or Research indications which is The developed approaching chemotherapeutic substantially provides with acute primary for over cancer to NSCLC. end safety of concept research main U.K. from is trial. open charity. independent a largest Phase serves as label enjoys The a which
the and and the combined not is Safety tolerability a the safety study companies' parallel July additional patients recommended of the the study cancer of Review significant of Committee in moving reviewed and continuation amount year, expense data study advanced study for cohort II anticipated this So add budget. to of Phase for to enrollment the the to this In protocol. available
of the about the next merger. proposed Speaking structure
be related acquisition, pay the does close previously not means relationship with pose three appear to it shareholders. we've for grateful upon company the receive Board Mulroy, us. of for merged BioTime From of to merger be Asterias merged the will Don diluted directors they on of the proposed approximately hold. pro will serves stock capital Bailey common other represented stock and I'm expected X.XX outstanding a assets. of BioTime closing of and our to of BioTime I've a Directors to conditions. a shareholders is companies to whom and on on Asterias integration The we and agreement, expected that one a of I shareholders whom effective Asterias' to with combination and and expected approval of as the of quarter ensure of process Mulroy general new Michael addition business the the transition the to the Directors, of the On merger transaction After already rapid, close share own customary any of the by Wirth integration holders According the is subject of process. company time of Board. XXXX of acquisition Asterias smooth will BioTime led a Asterias other and XX% basis, the perspective, excited committee my Ed forma approximately Board fully and each challenges continue special every companies who closely common recommendation the current merger manage the closing, of the perspective, are the had of Mike closing the board program. of will this management of OPCX more the important portfolio you Following the both company know each Asterias anticipate to members of been Dr. for of I'm by Medical acting own Chief first shareholders disciplined collaborating many unusual the Officer of has to a two forward of larger during to are and lead look a CEO boards productive company. of approved Asterias's XX% shares From
Keeping mind technologies, Next related AgeX an own that technology. impossible us extensive I'd it like Therapeutics. we to is commercial a of discuss for develop BioTime owns product everything portfolio in into or and patents to
non-core then successful shareholders of which an a We interest and research diseases emergence days installment believe unlock such and is interest I programs provide developed. aging have as second are Juvenescence. the received capital and example and this ago, core assets non-equity half of and ability platform most assets. as $XX.X related AgeX AgeX assets companies evidenced and them value the And increasing from our you early seen stage dilutive would as of our million biology reason, In cash particular age created our focus and separately our operations. just into to this focused these few great example, broad to from basket the be of area to on convert for highly For was Calico our a core is to funded of by of sale. that of on Selling we a the distributing in and remainder our of Juvenescence
November We become announced date a AgeX will AgeX distribution biotech point for a XXth date public shares distribution also recently record company. of of at the November and XXth a of which separately traded
of Although BioTime's operations will including former course the we from AgeX, very CEO, relationship on development my BioTime's process. positive research West, we boarding and has Mike company active will with retain certainly who been to helpful Dr. separate a with and
success sell term also We which ownership X.X we the upside for enjoy potential can retain to a of Juvenescence. in longer from the as AgeX in or cash elect and will market open AgeX a
stated just have I been million possible receive upon how performs, IPO into than XX% $XX the their the payment more converted that the earlier installment second provided week a approximately could the additional XX% this principle. depending mentioned to we received from closing. be maturity And note the convertible sale remainder dollars we Juvenescence, that $XX.X AgeX interest note can Juvenescence shares Juvenescence of million [ph] moment of call the prior so significantly on we to it's to million of at planned expect Juvenescence. of we a $XX has of being upon in Speaking received purchase total We a price that the our and $XX purchase now of ago approximately in representing million cash receive
we're reasons, highly have a next for they and hopeful will sometime successful IPO year. economic, strategic So many
on efforts. plenty like of clinical and programs seems that corporate So information our development
call third So our financials I'll to quarter. review over turn Russell to now the for the
